Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | lamin | 0.0033 | 0.3537 | 1 |
Onchocerca volvulus | 0.0033 | 0.3537 | 0.5 | |
Echinococcus multilocularis | musashi | 0.0033 | 0.3537 | 1 |
Schistosoma mansoni | lamin | 0.0033 | 0.3537 | 0.6116 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 0.3537 | 0.3537 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.5545 | 0.5545 |
Echinococcus granulosus | intermediate filament protein | 0.0033 | 0.3537 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 1 | 1 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0019 | 0.0375 | 0.0375 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.3397 | 0.3397 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.3537 | 0.3537 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.5545 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 1 | 1 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 0.3537 | 0.3537 |
Echinococcus multilocularis | lamin dm0 | 0.0033 | 0.3537 | 1 |
Brugia malayi | intermediate filament protein | 0.0033 | 0.3537 | 0.3537 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.5545 | 0.5545 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0019 | 0.0375 | 0.0375 |
Onchocerca volvulus | 0.0033 | 0.3537 | 0.5 | |
Echinococcus granulosus | lamin dm0 | 0.0033 | 0.3537 | 1 |
Schistosoma mansoni | intermediate filament proteins | 0.0033 | 0.3537 | 0.6116 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0019 | 0.0375 | 0.0375 |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 0.3537 | 0.3537 |
Schistosoma mansoni | lamin | 0.0033 | 0.3537 | 0.6116 |
Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.0375 | 0.0375 |
Echinococcus granulosus | lamin | 0.0033 | 0.3537 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 0.005 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 0.3981 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 10 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent). (Class of assay: confirmatory) [Related pubchem assays: 2158 (Confirmation qHTS Assay for Inhibitors of Cruzain), 2249 (Probe Development Summary of Promiscuous Inhibitors (Artifacts) of Cruzain), 2161 (qHTS Assay for Inhibitors of Papain: Counterscreen for Cruzain Assay), 1478 (qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent))] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.